FDA Guidance News In Brief
This article was originally published in The Gray Sheet
HIV drug resistance testing: Aug. 8 guidance describes two pathways - one involving only analytical testing and the other combining analytical and clinical testing - for 510(k) clearance of assays that detect HIV mutations associated with drug resistance. The Class II special controls guidance accompanies a rule reclassifying HIV drug resistance genotype assays from Class III to II...
You may also be interested in...
FDA released a final rule on protections for children in clinical trials and a final guidance on financial disclosures by investigators. More regulatory news.
The advent of stem cell therapy to future medicine will be facilitated by medical devices that actually process and store the cells. At least two firms already see near-term opportunities to pioneer the technology
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.